This is unsettling to researchers such as Brian Earp, an Oxford University neuroethicist who published a paper last year on anti-love biotechnology. "Since these kinds of interventions are very likely to be developed," he says, "we need to start an ethical discussion now." Earp argues that any such drugs should be voluntary, concomitant with therapy, and monitored for misuse. After all, he says, "There's a long history of attempting to harness biomedicine to diminish same-sex sexuality." But Neil McArthur, a philosophy professor at the University of Manitoba in Winnipeg, Canada, points out situations in which drugs might make sense: cases of pedophilia or abuse, for example, in which people are "behaving in a way that's potentially destructive."